汉商集团股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 证券代码：600774 证券简称：汉商集团 公告编号：2025-045 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 29 日 14 点 30 分 召开地点：武汉市汉阳区汉阳大道 134 号公司本部 801 会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 29 日 至2025 年 12 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股 ...

本次会议审议通过了《关于修订<公司章程>并取消监事会的议案》。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 汉商集团股份有限公司（以下简称"公司"）于2025年12月5日以网络传输 的方式发出关于召开第十二届监事会第五次会议（以下简称"本次会议"）的通 知及会议材料。本次会议于2025年12月10日以通讯表决方式召开，应出席监事3 人，实际出席3人。本次会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的规定。 二、监事会会议审议情况 证券代码：600774 股票简称：汉商集团 编号：2025-043 汉商集团股份有限公司 第十二届监事会第五次会议决议公告 根据《中华人民共和国公司法》（以下简称"《公司法》"）、中国证监会《关 于新<公司法>配套制度规则实施相关过渡期安排》《上市公司章程指引》等相关 法律法规的规定，公司将不再设置监事会，由董事会审计委员会行使《公司法》 规定的监事会的职权，《监事会议事规则》相应废止，公司各项规章制度中涉及 监事会、监事的规定不再适用，并相应修 ...

证券代码：600774 股票简称：汉商集团 编号：2025-042 汉商集团股份有限公司 第十二届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 汉商集团股份有限公司（以下简称"公司"）于 2025 年 12 月 5 日以网络传 输的方式发出关于召开第十二届董事会第六次会议（以下简称"本次会议"）的 通知及会议材料。本次会议于 2025 年 12 月 10 日以通讯表决方式召开，应出席 董事 9 人，实际出席 9 人。本次会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 二、董事会会议审议情况 （一）本次会议审议通过了《关于修订<公司章程>并取消监事会的议案》。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、中国证监会《关 于新<公司法>配套制度规则实施相关过渡期安排》《上市公司章程指引》等相关 法律法规的规定，公司将不再设置监事会，由董事会审计委员会行使《公司法》 规定的监事会的职权，《监事会议事规则》相应废止，公司各项规章制度中涉及 ...

汉商集团股份有限公司 第二条 公司和其他信息披露义务人（以下统称"信息披露义务人"）暂缓、 豁免披露临时报告，在定期报告、临时报告中豁免披露中国证券监督管理委员会 （以下简称"中国证监会"）和上海证券交易所规定或者要求披露的内容，适用 本制度。 第三条 信息披露义务人应当真实、准确、完整、及时、公平地披露信息， 不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实施内幕交易、 操纵市场等违法行为。 第四条 信息披露义务人应当审慎确定信息披露暂缓、豁免事项，履行内部 审核程序后实施。 第二章 暂缓、豁免信息的范围和条件 第五条 信息披露义务人有确实充分的证据证明拟披露的信息涉及国家秘密 或者其他因披露可能导致违反国家保密规定、管理要求的事项（以下统称"国家 秘密"），依法豁免披露。 第六条 信息披露义务人有保守国家秘密的义务，不得通过信息披露、投资 者互动问答、新闻发布、接受采访等任何形式泄露国家秘密，不得以信息涉密为 名进行业务宣传。 1 信息披露暂缓与豁免业务管理制度 第一章 总则 第一条 为规范汉商集团股份有限公司(以下简称"公司")信息披露暂缓与 豁免行为，保证公司依法合规履行信息披露义务，根据 ...

Core Viewpoint - Han Commercial Group (600774.SH) reported a decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 251 million, representing a year-on-year decrease of 9.70% [1] - The net profit attributable to shareholders of the listed company was 7.704 million [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -17.9754 million [1]

Group 1 - The core viewpoint of the article highlights that Han Commercial Group reported a revenue decline of 15.49% year-on-year for the first three quarters of 2025, amounting to approximately 764 million yuan, while net profit attributable to shareholders increased by 274.07% to around 9.33 million yuan [1] - As of the report, Han Commercial Group has a market capitalization of 2.8 billion yuan [1]

证券代码：600774 证券简称：汉商集团 公告编号：2025-041 汉商集团股份有限公司 2025年1-3季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 单位：元 币种：人民币 | | | | 主营业务分产品情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分产 | 营业收入 | 营业成本 | 毛利率 | 营业收入比 上年同期增 | 营业成本比 上年同期增 | 毛利率比上 年同期增减 | | 品 | | | （%） | 减（%） | 减（%） | （%） | | 中药 | 153,563,002.93 | 95,586,741.17 | 37.75 | -17.62 | 16.11 | 减少 18.09 个百分点 | | 化药 | 364,623,797.42 | 272,998,784.29 | 25.13 | -15.92 | 0.12 | 减少 11.99 个百分点 | 1 | 医疗 | | | | | | 减少 个 0.13 | ...

Financial Performance - The company's operating revenue for the third quarter was CNY 250,876,068.98, a decrease of 9.70% compared to the same period last year[5]. - The total profit for the third quarter was CNY 12,902,755.42, with a year-to-date profit of CNY 19,307,709.99, reflecting an increase of 44.56% year-on-year[5]. - The net profit attributable to shareholders for the third quarter was CNY 7,703,958.19, while the year-to-date net profit reached CNY 9,325,415.72, showing a significant increase of 274.07% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2025 was CNY 763,757,910.80, a decrease of 15.5% compared to CNY 903,786,703.47 in the same period of 2024[25]. - Net profit for the first three quarters of 2025 was CNY 3,215,747.62, compared to a net loss of CNY 4,288,249.20 in the same period of 2024[25]. - Total comprehensive income for the period attributable to the parent company was CNY 9,335,605.36, compared to CNY 2,492,970.62 in the previous period, indicating a significant increase[27]. Earnings and Shareholder Information - The basic earnings per share for the third quarter was CNY 0.0261, and the diluted earnings per share was also CNY 0.0261, both reflecting an increase of 276.19% year-to-date[6]. - Basic and diluted earnings per share increased to CNY 0.0316 from CNY 0.0084 in the previous period, reflecting improved profitability[27]. - The company had a total of 20,652 ordinary shareholders at the end of the reporting period[12]. - The largest shareholder, Wuhan Hanyang Investment Development Group Co., Ltd., held 26.93% of the shares, totaling 79,444,603 shares[13]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,391,880,114.01, a decrease of 3.76% compared to the end of the previous year[6]. - The company's total assets decreased to CNY 3,391,880,114.01 from CNY 3,524,394,269.57 year-over-year[23]. - Current liabilities totaled CNY 1,355,716,508.24, a decrease of 5.1% from CNY 1,428,511,817.17 in the previous year[22]. - Long-term borrowings decreased to CNY 77,009,385.00 from CNY 137,007,387.00, reflecting a reduction of 43.9%[22]. Cash Flow and Financing - The net cash flow from operating activities for the year-to-date was CNY 72,179,925.69, a decrease of 46.92% compared to the previous year[5]. - Net cash flow from operating activities for the first three quarters of 2025 was CNY 72,179,925.69, down 46.8% from CNY 135,984,587.80 in the same period of 2024[30]. - Cash received from the sale of goods and services was CNY 965,036,334.82, a decrease of 15.4% compared to CNY 1,140,921,943.73 in the previous year[29]. - Total cash inflow from operating activities was CNY 1,033,050,416.94, down 13.1% from CNY 1,189,752,224.12 in the previous year[29]. - The company received CNY 427,867,724.22 in cash from borrowings, an increase of 47.2% compared to CNY 290,745,189.74 in the previous year[30]. Operational Challenges - The net cash flow from operating activities for the year-to-date was CNY 72,179,925.69, a decrease of 46.92% compared to the previous year[5]. - The company has a judicial freeze on several bank accounts, with balances as low as RMB 1.03, indicating potential liquidity issues[19]. - The company has pledged multiple properties as collateral for loans, including properties in Hanyang District, indicating a strategy to secure financing through asset-backed loans[16][17][18]. - The company has short-term loans totaling RMB 1,000,000.00 from Guangda Bank, RMB 32,000,000.00 from Agricultural Bank of China, and RMB 81,000,000.00 from Industrial Bank, indicating significant reliance on bank financing[16][17][18]. Other Financial Metrics - The weighted average return on equity at the end of the reporting period was 0.4624%, an increase of 0.82 percentage points compared to the end of the previous year[6]. - Research and development expenses for the first three quarters of 2025 were CNY 24,078,584.70, down 23.1% from CNY 31,267,422.13 in 2024[25]. - The company reported a significant increase in other income, totaling CNY 20,337,822.70 compared to CNY 10,672,474.97 in the previous year[25]. - The company experienced a credit impairment loss of CNY -3,442,603.40, contrasting with a gain of CNY 5,005,926.63 in the previous year[26]. - The company has not engaged in any share lending or borrowing activities during the reporting period, indicating a stable shareholder structure[15].

Core Points - The Shanghai Composite Index is at 3927.63 points, slightly down by 0.16%, with a total trading volume of 1.2446 trillion yuan [1] - A total of 181 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Li Min Co., Ltd. (002734) has a deviation rate of 4.31% with a price increase of 6.27% [1] - Yuanda Environmental Protection (600292) shows a deviation rate of 3.35% and a price increase of 3.93% [1] - Oriental Carbon (920175) has a deviation rate of 3.28% with an 8.17% price increase [1] Trading Activity - The total trading volume for A-shares today is reported at 1.2446 trillion yuan [1] - The stocks with the smallest deviation rates include Lian Ke Technology, Lingkang Pharmaceutical, and Publishing Media, which have just crossed the half-year line [1] Deviation Rate Rankings - The top stocks with the highest deviation rates include: - Li Min Co., Ltd. (002734) at 4.31% - Yuanda Environmental Protection (600292) at 3.35% - Oriental Carbon (920175) at 3.28% [1] - Other notable stocks with significant price increases and deviation rates include: - Han Commercial Group (600774) at 3.19% - Rui Pu Biological (300119) at 2.99% [1]

证券代码：600774 股票简称：汉商集团 编号：2025-040 汉商集团股份有限公司 关于提供担保进展情况的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 1、担保人：汉商集团股份有限公司（以下简称"公司"）的全资子公司成都迪康药业 股份有限公司（以下简称"迪康药业"） 2、被担保人：重庆迪康长江制药有限公司（以下简称"迪康长江"） 3、新增担保金额：3,000万元 5、是否有反担保：无 一、担保情况概述 （一）担保基本情况 担保人与被担保人的关系：迪康长江为迪康药业的全资子公司。 迪康药业在公司股东大会批准担保额度内，为迪康长江在重庆三峡银行股 份有限公司万州分行贷款 3,000 万元提供保证担保，并与重庆三峡银行股份有 限公司万州分行签订《保证合同》（合同编号：渝三银 BZC02262025210002101 号）。 （二）年度预计担保使用情况 经公司 2025 年 4 月 29 日召开的 2024 年年度股东会审议通过的《关于续展 及新增担保额度的议案》，公司与控股子公司或控股子公司之间相互提供担保， 预计 ...